All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Acalabrutinib-Based Regimens Receive European Approval in Frontline CLL

June 6th 2025

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

FDA Receives NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

June 6th 2025

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

Pirtobrutinib Adds Effective Option to CLL Treatment Landscape, Underscoring Treatment Selection Considerations

June 6th 2025

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma

June 6th 2025

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia

June 5th 2025

Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.

Bispecific Antibodies Improve TTNT and Reshape R/R Follicular Lymphoma Management

June 5th 2025

Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.

Pancreatic Cancer Spreads to Liver or Lung Thanks to This Protein

June 5th 2025

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

June 5th 2025

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.

China’s NMPA Approves Cadonilimab Plus Chemo With/Without Bevacizumab in Cervical Cancer

June 5th 2025

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

China’s NMPA Accepts NDA for Sintilimab Plus Fruquintinib in Second-Line Advanced/Metastatic RCC

June 5th 2025

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA

Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC

June 5th 2025

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

Casdozokitug Plus Atezolizumab/Bevacizumab Yields Antitumor Activity in Unresectable, Advanced HCC

June 5th 2025

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

IMA203 Demonstrates Early Promise in PD-1–Refractory Metastatic Melanoma

June 5th 2025

IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.

Dr Mittendorf Charts Vision as ASCO President-Elect to Advance Multidisciplinary Care and Research Equity

June 5th 2025

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

June 4th 2025

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy

June 4th 2025

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

June 4th 2025

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Understanding Your Risk: Are Women Likelier to Have Thyroid Cancer Than Men Are?

June 4th 2025

Recent research at Mayo Clinic evaluated thyroid cancer risk in men and women.

THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC

June 4th 2025

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.